

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
19 August 2021 (19.08.2021)



(10) International Publication Number
WO 2021/163190 A1

(51) International Patent Classification:

A61K 31/7016 (2006.01) A61K 47/18 (2017.01)

A61K 47/12 (2006.01)

(21) International Application Number:

PCT/US2021/017453

(22) International Filing Date:

10 February 2021 (10.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/972,224 10 February 2020 (10.02.2020) US

(71) Applicant: **UNIVERSITY OF UTAH RESEARCH FOUNDATION** [US/US]; 615 Arapleen Drive, Suite 301, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(71) Applicants: **GLEICH, Gerald, J.** [US/US]; C/o University Of Utah, 201 President's Circle, Salt Lake City, UT 84112 (US). **CONDIE, Russell, Morris** [US/US]; C/o 201 University Of Utah, 201 President's Circle, Salt Lake City, UT 84112 (US). **ECKERT, Debbie** [US/US]; C/o 201 University Of Utah, 201 President's Circle, Salt Lake City, UT 84112 (US). **LEIFERMAN, Kristin, M.** [US/US]; C/o University Of Utah, 201 President's Circle, Salt Lake City, UT 84112 (US). **PETERSON, Kathryn, A.** [US/US]; C/o University Of Utah, 201 President's Circle, Salt Lake City, UT 84112 (US). **SAFFARI, Hedieh** [US/US]; C/o University Of Utah, 201 President's Circle, Salt Lake City, UT 84112 (US). **PEASE, Leonard** [US/US]; C/o University Of Utah, 201 President's Circle, Salt Lake City, UT 84112 (US).

(74) Agent: **KLIEM, Michele A.** et al.; Ballard Spahr LLP, 999 Peachtree Street, Suite 1000, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: HIGH MOLECULAR WEIGHT HEPARIN COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING AND MONITORING EOSINOPHIL MEDIATED INFLAMMATORY DISEASES

(57) Abstract: Disclosed herein are compositions comprising high molecular weight heparin. The compositions comprise an effective amount of high molecular weight heparin having an average molecular weight from about 20 kDa to about 40 kDa and having a purity of at least 50%, and a pharmaceutically acceptable excipient. Disclosed herein are also methods of treating eosinophil-related inflammation in a subject.

WO 2021/163190 A1